DTU Logo
Publications | Academic Presentations | Slidesets | Webcasts

Publications (365 of 365)

Search Publications :
On the potential of acarbose to reduce cardiovascular disease [Mandarin republication]
Standl E, Theodorakis MJ, Erbach M, Schnell O, Tuomilehto J, Pan CY
International Journal of Endocrinology and Metabolism 2016 (in press)
Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study: Metabolism
D. Preiss, N. Rankin, P. Welsh, R. R. Holman, A. J. Kangas, P. Soininen, P. Würtz, M. Ala-Korpela and N. Sattar
Diabetic Medicine 2016, Epub:16-Feb-2016, PMID:26887663, doi:10.1111/dme.13097
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
Darren K. McGuire,MD, MHSc; Frans Van deWerf, MD, PhD; PaulW. Armstrong, MD; Eberhard Standl, MD, PhD; Joerg Koglin, MD; Jennifer B. Green, MD; M. Angelyn Bethel, MD; Jan H. Cornel, MD; Renato D. Lopes, MD, MHS, PhD; Sigrun Halvorsen, MD; Giuseppe Ambrosio, MD; John B. Buse, MD; Robert G. Josse, MBBS; John M. Lachin, ScD; Michael J. Pencina, PhD; Jyotsna Garg, MS; Yuliya Lokhnygina, PhD; Rury R. Holman, MBChB; Eric D. Peterson, MD, MPH; for the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group
JAMA Cardiology 2016, Epub:13-Apr-2016, doi:10.1001/jamacardio.2016.0103
Rationale and Design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) Trial
Rury R. Holman, M. Angelyn Bethel, Jyothis George, Harald Sourij, Zoë Doran, Joanne Keenan, Nardev S. Khurmi, Robert J. Mentz, Abderrahim Oulhaj, John B. Buse, Juliana C. Chan, Nayyar Iqbal, Sudeep Kundu, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Michael J. Pencina, Neil Poulter, Lisa E. Porter, Ambady Ramachandran, Bernard Zinman, Adrian F.Hernande
American Heart Journal 2016;174:103-110, Published:Apr-2016, Epub:21-Dec-2015, doi:10.1016/j.ahj.2015.12.009
Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes
M.A. Bethel, P Harrison, H Sourij, Y Sun, L Tucker, I Kennedy , S White, L Hill, A Oulhaj, R Coleman, R.R. Holman
Diabetic Medicine 2016;33:224-230, Published:Feb-2016, Epub:14-Jul-2015, PMID:26043186, doi:10.1111/dme.12828
Adherence to Oral Glucose-Lowering Therapies and Associations WIth 1-year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database
Andrew J. Farmer, Lauren R Rodgers, Mike Lonergan, Beverley Shields, Michael Weedon, Louise Donnelly, Rury R. Holman, Ewan R. Pearson, Andrew T Hattersley for the MASTERMIND consortium
Diabetes Care 2016;39:258-263, Published:Feb-2016, Epub:17-Dec-2015, PMID:26681714, doi:10.2337/dc15-1194
2015TECOS Correspondence
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman, Eric D. Peterson
The New England Journal of Medicine 2015;373:2479, Published:17-Dec-2015, PMID:26672857, doi:10.1056/NEJMc1510995
Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study
David Preiss, Laine E Thomas, Daniel M Wojdyla, Steven M Haffner, Jason M R Gill, Thomas Yates, Melanie J Davies, Rury R Holman, John J McMurray, Robert M Califf, William E Kraus, on behalf of the NAVIGATOR investigators
BMJ Open 2015;5:e007901, Published:11-Nov-2015, Epub:14-Aug-2015, PMID:26275900, doi:10.1136/bmjopen-2015-007901
Short report
Cardiovascular outcome trials of glucose-lowering drugs in type 2 diabetes: 10 frequently asked questions
Jyothis George
Practical Diabetes 2015;32:301-304, Published:Oct-2015, Epub:16-Oct-2015, doi:10.1002/pdi.1976
GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study.
Michael J. Theodorakis
Diabetes 2015;64:e28-e29, Published:Sep-2015, Epub:01-Sep-2015, PMID:26294437, doi:10.2337/db15-0614
Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial
T. Yates, M. J. Davies, S. M. Haffner, P. J. Schulte, L. Thomas, K. M. Huffman, C. W. Bales, D. Preiss, R. M. Califf, R. R. Holman, J. J. V. McMurray, M. A. Bethel, J. Tuomilehto and W. E. Kraus
Diabetic Medicine 2015;32:1090-1096, Published:Aug-2015, Epub:12-Apr-2015, PMID:25818859, doi:10.1111/dme.12762
Physiology of GNRH and Gonadotropin Secretion
Pedro Marques, Karolina Skorupskaite, Kavitha S. Rozario, Richard A. Anderson and Jyothis T. George
Endotext 2015;1:1-30, Published:31-Jul-2015, PMID:25905297
Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice
Carla Francés Artigas, Victoria Stokes, Garry D Tan and Michael J Theodorakis
Expert Opin. Pharmacother. 2015;16:1417-1421, Published:17-Jul-2015, Epub:16-Jun-2015, PMID:26077113, doi:10.1517/14656566.2015.1052740
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, Robert Josse, Keith D. Kaufman, Joerg Koglin, Scott Korn, John M. Lachin, Darren K. McGuire, Michael J. Pencina, Eberhard Standl, Peter P. Stein, Shailaja Suryawanshi, Frans Van de Werf, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
N Engl J Med 2015;373:232-242, Published:16-Jul-2015, Epub:08-Jun-2015, PMID:26052984, doi:10.1056/NEJMoa1501352
Erratum in :
N Engl J Med 201;373:586, Print:06-Aug-2015, Epub:16-Jul-2015, PMID:26182233, doi:10.1056/NEJMx150029
The University of Oxford Diabetes Trials Unit
Mark Nicholls, Rury Holman
European Heart Journal 2015;36:1706-07, Published:14-Jul-2015, PMID:26393241
Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD
Jonathan C. Levy, Axel Riefflin & Rury R. Holman
Diabetologia 2015;58:1376-7, Published:Jun-2015, Epub:26-Mar-2015, PMID:25810041, doi:10.1007/s00125-015-3574-z
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial [Mandarin Abstract]
Hu Da Yi, Pan Chang Yu, Rury R. Holman.
Chinese Journal of Cardiology 2015;43:412, Published:24-May-2015, doi:10.3760/cma.j.issn.0253-3758.2015.05.008
How does obesity affect fertility in men - and what are the treatment options?
Victoria J. Stokes, Richard A. Anderson and Jyothis T. George
Clinical Endocrinology 2015;82:633-8, Published:May-2015, Epub:16-Sep-2014, PMID:25138694, doi:10.1111/cen.12591
Normal weight individuals with type 2 diabetes: The Personal Fat Threshold
Roy Taylor and Rury R. Holman
Clinical Science 2015;128:405-410, Published:01-Apr-2015, PMID:25515001, doi:10.1042/CS20140553
The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)
M. L. Alva, A. Gray, B. Mihaylova, J. Leal and R. R. Holman
Diabetic Medicine 2015;32:459-466, Published:Apr-2015, Epub:07-Jan-2015, PMID:25439048, doi:10.1111/dme.12647
Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M. A. Bethel, J. B. Green, J.Milton, A.Tajar, S.S.Engel, R.M.Califf, R.R.Holman on behalf of the TECOS Executive Committee
Diabetes, Obesity and Metabolism 2015;17:395-402, Published:Apr-2015, Epub:13-Feb-2015, PMID:25600421, doi:10.1111/dom.12441
Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials
The Blood Pressure Lowering Treatment Trialists’ Collaboration
Lancet 2015;385:867-74, Published:07-Mar-2015, Epub:04-Nov-2014, PMID:25468168, doi:10.1016/S0140-6736(14)61171-5
Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
M. A. Bethel, W. Xu, M. J. Theodorakis
Diabetes, Obesity and Metabolism 2015;17:231-244, Published:Mar-2015, Epub:27-Nov-2014, PMID:25312701, doi:10.1111/dom.12401
The effect of glibenclamide on insulin secretion at normal glucose concentrations
Axel Riefflin, Usha Ayyagari, Susan E. Manley, Rury R. Holman, Jonathan C. Levy
Diabetologia 2015;58:43-49, Published:Jan-2015, Epub:09-Oct-2014, PMID:25297572, doi:10.1007/s00125-014-3399-1
Chronic Obstructive Pulmonary Disease and Cardiovascular Risk: Insights from the NAVIGATOR Trial
Pedro G.M. de Barros e Silva, Robert M. Califf, Jie-Lena Sun, John J.V. McMurray, Rury R. Holman, Steven Haffner, Laine Thomas, Renato D. Lopes
International Joural of Cardiology 2014;176:1126-1128, Published:25-Mar-2015, Epub:12-Aug-2014, PMID:25220176, doi:10.1016/j.ijcard.2014.07.297
Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study
D. Preiss, S. M. Haffner, L. E.Thomas, J.-L. Sun, N. Sattar, T. Yates, M. J Davies, J. J. McMurray, R. R. Holman, R. M. Califf & W. E. Kraus
Diabetes Obesity and Metabolism 2014;16:1265-1268, Published:Dec-2014, Epub:19-Jun-2014, PMID:24861892, doi:10.1111/dom.12320
UKPDS Letter
Performance of the UKPDS Outcomes Model for Prediction of Myocardial Infarction and Stroke in the ADDITION-Europe Trial Cohort: does the ADDITION validation add up?
Alastair Gray, Rury Holman, Philip Clarke, Jose Leal
Value in Health 2014;17:895-6, Published:Dec-2014, Epub:22-Sep-2014, PMID:25498785, doi:10.1016/j.jval.2014.07.008
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
Prof John J V McMurray MD, Prof Hertzel C Gerstein MD, Prof Rury R Holman FRCP, Prof Marc A Pfeffer MD
The Lancet 2014;2:843-851, Published:Oct-2014, Epub:13-Mar-2014, PMID:24731668, doi:10.1016/S2213-8587(14)70031-2
Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes. Authors' reply
Rury R. Holman, Harald Sourij, Robert M. Califf
The Lancet 2014;384:1097-1098, Published:20-Sep-2014, PMID:25241719, doi:10.1016/S0140-6736(14)61674-3
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
The Blood Pressure Lowering Treatment Trialists' Collaboration
The Lancet 2014;384:591-598, Published:16-Aug-2014, Epub:14-Aug-2014, PMID:25131978, doi:10.1016/S0140-6736(14)61212-5
Cardiovascular endocrinology: First-time heart failure increases risk of diabetes mellitus
Rury R. Holman
Nat. Rev. Endocrinol. 2014;10:453-454, Published:Aug-2014, Epub:01-Jul-2014, PMID:24981458, doi:10.1038/nrendo.2014.105
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Rury R Holman, Mary A Bethel, Juliana CN Chan, Jean-Louis Chiasson, Zoë Doran, Junbo Ge, Hertzel Gerstein, Yong Huo, John J McMurray, Lars Ryden, Winitha Liyanage, Stefan Schröder, Michal Tendera, Michael J Theodorakis, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan for the ACE Study Group
American Heart Journal 2014;168:23-29, Published:Jul-2014, Epub:05-Apr-2014, PMID:24952856, doi:10.1016/j.ahj.2014.03.021
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Rury R Holman, Harald Sourij, Robert M Califf
Lancet 2014;383:2008-17, Published:07-Jun-2014, Epub:05-Jun-2014, PMID:24910232, doi:10.1016/S0140-6736(14)60794-7
On the potential of acarbose to reduce cardiovascular disease
Eberhard Standl, Michael J Theodorakis, Michael Erbach, Oliver Schnell and Jaakko Tuomilehto
Cardiovascular Diabetology 2014;13:81, Published:16-Apr-2014, PMID:24742256, doi:doi:10.1186/1475-2840-13-81
Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR
Huffman KM, Sun JL, Thomas L, Bales CW, Califf RM, Yates T, Davies MJ, Holman RR, McMurray JJ, Bethel MA, Tuomilehto J, Haffner SM, Kraus WE.
Metabolism 2014;63:554-561, Published:Apr-2014, Epub:15-Jan-2014, PMID:24559843, doi:10.1016/j.metabol.2014.01.002
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis
Thomas Yates, Steven M Haff ner, Phillip J Schulte, Laine Thomas, Kim M Huff man, Connie W Bales, Robert M Califf , Rury R Holman, John J V McMurray, M Angelyn Bethel, Jaakko Tuomilehto, Melanie J Davies, William E Kraus
Lancet 2014;383:1059-66, Published:22-Mar-2014, Epub:20-Dec-2013, PMID:24361242, doi:10.1016/S0140-6736(13)62061-9
Ethnicity and long-term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83)
T. M. E. Davis, R. L. Coleman and R. R. Holman for the UKPDS Group
Diabetic Medicine 2014;31:200-207, Published:Feb-2014, Epub:22-Nov-2013, PMID:24267048, doi:10.1111/dme.12353
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial
David Preiss, Suzanne M Lloyd, Ian Ford, John J McMurray, Rury R Holman, Paul Welsh, Miles Fisher, Chris J Packard, Naveed Sattar
Lancet Diabetes & Endocrinology 2014;2:116-124, Published:Feb-2014, Epub:07-Nov-2013, PMID:24622715, doi:10.1016/S2213-8587(13)70152-9
Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study
Lan Shen, Bimal R Shah, Eric M Reyes, Laine Thomas, Daniel Wojdyla, Peter Diem, Lawrence A Leiter, Bernard Charbonnel, Viacheslav Mareev, Edward S Horton, Steven M Haffner, Vladimir Soska, Rury Holman, M Angelyn Bethel, Frank Schaper, Jie-Lena Sun, John JV McMurray, Robert M Califf, Henry Krum
British Medical Journal 2013;347:f6745, Published:09-Dec-2013, PMID:24322398, doi:10.1136/bmj.f6745
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman
American Heart Journal 2013;166:983-989.e7, Published:Dec-2013, Epub:23-Oct-2013, PMID:24268212, doi:10.1016/j.ahj.2013.09.003
UKPDS - The first 30 years (Mandarin version)
Holman RR, Watkins PJ
2013; , Published:18-Nov-2013
Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial
Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F, Giles TD, Maggioni AP, Rutten GE, Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJ
American Heart Journal 2013;166:935-940.e1, Published:Nov-2013, Epub:07-Oct-2013, PMID:24176451, doi:10.1016/j.ahj.2013.08.012
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial
David Preiss, Thomas D. Giles, Laine E. Thomas, Jie-Lena Sun, Steven M. Haffner, Rury R. Holman, Eberhard Standl, Theodore Mazzone, Guy E. Rutten, Gianni Tognoni, Fu-Tien Chiang, John J.V. McMurray, Robert M. Califf
Stroke 2013;44:2590-2593, Published:Sep-2013, Epub:30-Jul-2013, PMID:23899915, doi:10.1161/STROKEAHA.113.001177
Outcomes Model / UKPDS 82
UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM
Diabetologia 2013;56:1925-1933, Published:Sep-2013, Epub:22-Jun-2013, PMID:23793713, doi:10.1007/s00125-013-2940-y
A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk
Bethel MA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, Kahn SE, Levitt NS, McMurray JJ, Califf RM, Raptis SA, Thomas L, Sun JL, Haffner SM
Am J Cardiol 2013;112:231-237, Published:15-Jul-2013, Epub:19-Apr-2013, PMID:23608615, doi:10.1016/j.amjcard.2013.03.019
Temporal Validation of the UKPDS Outcomes Model Using 10-Year Post trial Monitoring Data
Leal J, Hayes AJ, Gray AM, Holman RR, Clarke PM.
Diabetes Care 2013;36:1541-1546, Published:Jun-2013, Epub:28-Dec-2012, PMID:23275370, doi:10.2337/dc12-1120
Evaluation of a Self-Administered Oral Glucose Tolerance Test
M. Angelyn Bethel, Hermione C. Price, Harald Sourij, Sarah White, Ruth L. Coleman, Arne Ring, Irene E. C. Kennedy, Lynne Tucker, and Rury R. Holman
Diabetes Care 2013;36:1483-1488, Published:Jun-2013, Epub:15-Jan-2013, PMID:23321216, doi:10.2337/dc12-0643
Metformin and mortality. Reply to Lund SS
R. J. Stevens, B. J. Cairns , R. R. Holman
Diabetologia 2013;56:939-940, Published:Apr-2013, Epub:09-Feb-2013, PMID:23397291, doi:10.1007/s00125-013-2844-x
Prognostic Significance of Silent Myocardial Infarction in Newly-Diagnosed Type 2 Diabetes: UKPDS 79
Timothy M.E. Davis; Ruth L. Coleman; Rury R. Holman
Circulation 2013;127:980-987, Published:05-Mar-2013, Epub:29-Jan-2013, PMID:23362315, doi:10.1161/CIRCULATIONAHA.112.000908
Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive
Holman RR
Nature Reviews Endocrinology 2013;9:67-68, Published:Feb-2013, Epub:08-Jan-2013, PMID:23296166, doi:10.1038/nrendo.2012.243
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
David Preiss, Laine E Thomas, Jie-Lena Sun, Steven M Haffner, Rury R Holman, Eberhard Standl, Lawrence A Leiter, Theodore Mazzone, Guy E Rutten, Gianni Tognoni, Felipe A Martinez, Fu-Tien Chiang, Robert M Califf, John J McMurray
BMJ Open 2012;2:e001925, Published:30-Nov-2012, Epub:30-Nov-2012, PMID:23204139, doi:10.1136/bmjopen-2012-001925
Editorial: Warning signals from clinical trials: all that glitters is not gold (Chinese translation)
Rury R Holman
Chinese Journal of Diabetes Mellitus 2012;4:513-516, Published:17-Oct-2012
Correspondence: Prediabetes and the risk of diabetes
John JV McMurray, Steven M Haffner, Robert M Califf, Rury R Holman
The Lancet 2012;380:1225-1226, Published:06-Oct-2012, PMID:23040850, doi:10.1016/S0140-6736(12)61706-1
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
R.J. Stevens, R.Ali, C.R. Bankhead, M.A. Bethel, B.J. Cairns, R.P. Camisasca, F.L. Crowe, A.J. Farmer, S. Harrison, J.A. Hirst, P. Home, S.E. Kahn, J.H. McLellan, R. Perera, A. Plüddemann, A. Ramachandran, N.W. Roberts, P.W. Rose, A. Schweizer, G. Viberti, R. R. Holman
Diabetologia 2012;55:2593-2603, Published:Oct-2012, Epub:10-Aug-2012, PMID:22875195, doi:10.1007/s00125-012-2653-7
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
John J.V. McMurray, Robert M. Califf, Angelyn M. Bethel, Steven M. Haffner, Rury R. Holman
The Journal of Clinical Hypertension 2012;14:731, Published:Oct-2012, Epub:26-Jul-2012, PMID:23031154, doi:10.1111/j.1751-7176.2012.00687.x
Disseminating results to clinical trial participants: a qualitative review of patient understanding in a post-trial population
Julie Lorraine Darbyshire, Hermione Clare Price
BMJ Open 2012;2:e001252, Published:24-Sep-2012, PMID:23012330, doi:10.1136/bmjopen-2012-001252
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts
van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, Stricker BH, Uitterlinden AG, Hofman A, van 't Riet E, Palmer CN, Guigas B, Slagboom PE, Durrington P, Calle RA, Neil A, Hitman G, Livingstone SJ, Colhoun H, Holman RR, McCarthy MI, Dekker JM, 't Hart LM, Pearson ER.
Diabetologia 2012;55:1971-7, Published:Jul-2012, Epub:28-Mar-2012, PMID:22453232, doi:10.1007/s00125-012-2537-x
Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice
Hermione C Price, Catherine Gorst, Usha Ayyagari, Jonathan Levy and Rury R Holman
Practical Diabetes 2012;29:61-64, Published:Mar-2012, Epub:06-Mar-2012, doi:10.1002/pdi.1660
Letter in response to Wannamethee et al: Women develop diabetes at higher BMIs than men
H. Sourij, R. R. Holman
Diabetologia 2012;55:855-6, Published:Mar-2012, Epub:06-Jan-2012, PMID:22222506, doi:10.1007/s00125-011-2437-5
Understanding the outcomes of multi-centre clinical trials: a qualitative study of health professional experiences and views
Lawton J, Jenkins N, Darbyshire J, Farmer A, Holman R, Hallowell N
Social Science & Medicine 2012;74:574-81, Published:Feb-2012, Epub:23-Dec-2011, PMID:22236642, doi:10.1016/j.socscimed.2011.11.012
Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice
M. Angelyn Bethel & Harald Sourij
Current Cardiology Reports 2012;14:59-69, Published:Feb-2012, Epub:18-Nov-2011, PMID:22094711, doi:10.1007/s11886-011-0229-7
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial
Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield JL, Ramachandran A, Riddle MC, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein HC; TIDE Trial Investigators.
Diabetologia 2012;55:36-45, Published:Jan-2012, Epub:29-Oct-2011, PMID:22038523, doi:10.1007/s00125-011-2357-4
2011All That Glitters Is Not Gold: Why we need better trials and reporting
Rury R Holman
Diabetes Voice 2011;56:32, Published:Dec-2011, PMID:21767341, doi:10.1111/j.1463-1326.2011.01475.x
Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Farmer AJ, Oke J, Stevens R, Holman RR
Diabetes, Obesity and Metabolism 2011;13:1136-1141, Published:16-Nov-2011, doi:10.1111/j.1463-1326.2011.01475.x
Incidence of Diabetes Following Ramipril and Rosiglitazone Withdrawal
Rury R Holman FRCP, B Zinman, S Yusaf, P Sheridan, S Anand, J Bosch, I Conget, M Davies, V Pirags, J Pogue, P Zimmet, HC Gerstein.
Diabetes Care 2011;34:1265-1269 , Published:Jun-2011, Epub:22-Apr-2011, PMID:21515846, doi:10.2337/dc10-1567
Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial
Julia Lawton, Nicholas Jenkins, Julie L Darbyshire, Rury R Holman, Andrew J Farmer and Nina Hallowell
Trials 2011;12: , Published:04-May-2011, PMID:21542916, doi:10.1186/1745-6215-12-108
Effects Of Rosiglitazone, Glyburide, and Metformin on beta-Cell Function and Insulin Sensitivity in ADOPT
Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR; and the ADOPT Study Group
Diabetes 2011;60:1552-1560, Published:May-2011, Epub:17-Mar-2011, PMID:21415383, doi:10.2337/db10-1392
Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
John M. Lachin, Giancarlo Viberti, Bernard Zinman, Steven M. Haffner, R. Paul Aftring, Gitanjali Paul, Barbara G. Kravitz, William H. Herman, Rury R. Holman, Steven E. Kahn, ADOPT
Clin J Am Soc Nephrol 2011;6:1032-40, Published:May-2011, Epub:31-Mar-2011, PMID:21454723, doi:10.2215/CJN.09291010
Patients' experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study
N. Jenkins, N. Hallowell, A. J. Farmer, R. R. Holman, J. Lawton
Diabetic Medicine 2011;28:543-548, Published:May-2011, PMID:21480965, doi:10.1111/j.1464-5491.2010.03200.x
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals
The ARB Trialists Collaboration
Journal of Hypertension 2011;29:623-635, Published:Apr-2011, Epub:10-Feb-2011, PMID:21358417, doi:10.1097/HJH.0b013e328344a7de
Errata in :
Journal of Hypertension 2015;32:288, Print:Feb-2015, Epub:20-Jan-2015, doi:10.1111/dme.12672
Journal of Hypertension 2011;28:625, Print:May-2011, Epub:12-Apr-2011, doi:10.1111/j.1464-5491.2011.03267.x
Impact of personalised cardiovascular disease risk estimates on physical activity-a randomised controlled trial
Hermione C Price, Simon J Griffin, Rury R Holman
Diabetic Medicine 2011;28:363-372, Published:Mar-2011, Epub:10-Feb-2011, PMID:21309847, doi:10.1111/j.1464-5491.2010.03212.x
Erratum in :
Diabetic Medicine 2015;32:288, PMID:Feb-2015
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group & The Wellcome Trust Case Control Consortium
Nature Genetics 2010;43:117-120, Published:Feb-2011, Epub:26-Dec-2010, PMID:21186350, doi:10.1038/ng.735
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled trial
H.A.W. Neil, U. Ceglarek, J. Thiery, S. Paul, A. Farmer, R. R Holman
Atherosclerosis 2010;213:512-517, Published:Dec-2010, Epub:18-Sep-2010, PMID:21036355, doi:10.1016/j.atherosclerosis.2010.09.013
Initiating insulin as part of the Treating to Target in Type 2 Diabetes (4-T) trial: A interview study of patients' and health care professionals' experiences
Nicholas Jenkins, Nina Hallowell, Andrew J. Farmer, Rury R. Holman, Julia Lawton
Diabetes Care 2010;33:2178-2180, Published:Oct-2010, Epub:30-Jun-2010, PMID:20592050, doi:10.2337/dc10-0494
Recommendations for Biomarker Identification and Qualification in Clinical Proteomics
Harald Mischak, Günter Allmaier, Rolf Apweiler, Teresa Attwood, Marc Baumann, Ariela Benigni, Samuel E. Bennett, Rainer Bischoff, Erik Bongcam-Rudloff, Giovambattista Capasso, Joshua J. Coon, Patrick D'Haese, Anna F. Dominiczak, Mohammed Dakna, Hassan Dihazi, Jochen H. Ehrich, Patricia Fernandez-Llama, Danilo Fliser, Jorgen Frokiaer, Jerome Garin, Mark Girolami, William S. Hancock, Marion Haubitz, Denis Hochstrasser, Rury R. Holman, John P. A. Loannidis, Joachim Jankowski, Bruce A. Julian, Jon B. Klein, Walter Kolch, Theo Luider, Ziad Massy, William B. Mattes, Franck Molina, Bernard Monsarrat, Jan Novak, Karlheinz Peter, Peter Rossing, Marta Sánchez-Carbayo, Joost P. Schanstra, O. John Semmes, Goce Spasovski, Dan Theodorescu, Visith Thongboonkerd, Raymond Vanholder, Timothy D. Veenstra, Eva Weissinger, Tadashi Yamamoto, Antonia Vlahou
Science Translational Medicine 2010;2:46ps42, Published:25-Aug-2010, PMID:20739680, doi:10.1126/scitranslmed.3001249
Life Expectancy in Individuals with Type 2 Diabetes: Implications for Annuities
Hermione C. Price, Philip M. Clarke, Alastair M. Gray and Rury R. Holman
Medical Decision Making 2010;30:409-14, Published:20-May-2010, Epub:30-Dec-2009, PMID:20042534, doi:10.1177/0272989X09349960
Risk communication: Why, what and how?
Hermione C Price
Diabetes & Primary Care 2010;12:100-104, Published:May-2010
[Full text]
Meta-analysis on insulin treatment for type 2 diabetes: rushed conclusions? Reply to Wägner AM, Mauricio D
A. J. Farmer & D. S. Lasserson & R. R. Holman
Diabetologia 2010;53:1004-5, Published:May-2010, Epub:23-Feb-2010, doi:10.1007/s00125-010-1679-y
Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials
Henry Krum, John J.V. McMurray, Edward Horton, Teresa Gerlock, Bjoern Holzhauer, Lineke Zuurman, Steven M. Haffner, M. Angelyn Bethel, Rury R. Holman, Robert M. Califf
Cardiovascular Therapeutics 2010;28(2):124-132, Published:29-Apr-2010, PMID:20184589, doi:10.1111/j.1755-5922.2010.00146.x
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010;362:1463-76, Published:22-Apr-2010, Epub:14-Mar-2010, PMID:20228402, doi:10.1056/NEJMoa1001122
[Presentation] [Slides]
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010;362:1477-90, Published:22-Apr-2010, Epub:14-Mar-2010, PMID:20228403, doi:10.1056/NEJMoa1001121
[Presentation] [Slides]
Erratum in :
N Engl J Med 2010;362:1748, Print:06-May-2010
Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis
Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ
Lancet 2010;375:1365-1374, Published:17-Apr-2010, Epub:29-Mar-2010, PMID:20356621, doi:10.1016/S0140-6736(09)62162-0
Erratum in :
Lancet 2010;375:1346, Print:17-Apr-2010
Evaluation of Serum 1,5 Anhydroglucitol Levels as a Clinical Test to Differentiate Subtypes of Diabetes
Aparna Pal, Christina Dudley, Mary Selwood, Beryl Barrow, Rhiannon Klyne, Jilly Grew, Andrew Farmer, Mark McCarthy, Anna Gloyn, Katharine Owen
Diabetes Care 2010;33:252-257, Published:Feb-2010, Epub:23-Nov-2009, PMID:19933992, doi:10.2337/dc09-1246
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)
Steven E. Kahn, Steven M. Haffner, Giancarlo Viberti, William H. Herman, John M. Lachin, Barbara G. Kravitz, Dahong Yu, Gitanjali Paul, Rury R. Holman, Bernard Zinman and for the ADOPT Study Group
Diabetes Care 2010;33:177-183, Published:Jan-2010, Epub:06-Oct-2009, PMID:19808911, doi:10.2337/dc09-1661
2009Exenatide Case Report
Price HC, Holman RR
International Diabetes 2009;15:15, Published:24-Jan-2011
[Full text]
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Bernard Zinman, Steven M. Haffner, William H. Herman, Rury R. Holman, John M. Lachin, Barbara G. Kravitz, Gitanjali Paul, Nigel P. Jones, R. Paul Aftring, Giancarlo Viberti, Steven E. Kahn, and the A Diabetes Outcome Progression Trial Study Group
J Clin Endocrinol Metab 2009;95:134-142, Published:Jan-2010, Epub:29-Oct-2009, PMID:19875477, doi:10.1210/jc.2009-0572
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin, Bernard Zinman
Clinical Diabetes 2009;27:4-16, Published:21-Dec-2009, doi:10.2337/diaclin.27.1.4
Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population
M. A. Bethel, P. Deedwania, N. S. Levitt, O. Schmitz, A. Huntsman-Labed, R. M. Califf, S. M. Haffner and P. Diem for the NAVIGATOR Study Groupp
Diabetic Medicine 2009;26:1204-1211, Published:Dec-2009, Epub:30-Sep-2009, PMID:20002471, doi:10.1111/j.1464-5491.2009.02864.x
Perceptions of heart attack risk amongst individuals with diabetes
Hermione C Price, Christina Dudley, Beryl Barrow, Simon J Griffin & Rury R Holman
Primary Care Diabetes 2009;3:239 -244, Published:Nov-2009, Epub:05-Nov-2009, PMID:19896425, doi:10.1016/j.pcd.2009.09.005
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull, C. Abraira, R. J. Anderson, R. P. Byington, J. P. Chalmers, W. C. Duckworth, G. W. Evans, H. C. Gerstein, R. R. Holman, T. E. Moritz, B. C. Neal, T. Ninomiya, A. A. Patel, S. K. Paul, F. Travert and M. Woodward
Diabetologia 2009;52:2288-2298, Published:Nov-2009, Epub:05-Aug-2009, PMID:19655124, doi:10.1007/s00125-009-1470-0
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman, Andrew J. Farmer, Melanie J. Davies, Jonathan C. Levy, Julie L. Darbyshire, Joanne F. Keenan, and Sanjoy K. Paul for the 4-T Study Group
N Eng J Med 2009;361:1736-47, Published:29-Oct-2009, Epub:22-Oct-2009, PMID:19850703, doi:10.1056/NEJMoa0905479
Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses
Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ
Diabetologia 2009;52:1990-2000, Published:Oct-2009, Epub:31-Jul-2009, PMID:19644668, doi:10.1007/s00125-009-1468-7
Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes
Price HC, Dudley C, Barrow B, Kennedy IA, Griffin SJ, Holman RR
Family Practice 2009;26:351-358, Published:Oct-2009, Epub:21-Jun-2009, PMID:19546119, doi:10.1093/fampra/cmp041
Presenting the results of clinical trials to participants
Julie L Darbyshire, Rury R Holman and Hermione C Price
Clin Med 2009;9:415-416, Published:Oct-2009, PMID:19886097, doi:10.7861/clinmedicine.9-5-415
Cardiovascular disease risk estimation: Why, when and how?
Price HC
Diabetes and Primary Care 2009;11:218-223, Published:Aug-2009
[Full text]
International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, Davidson MB, DeFronzo R, Genuth S, Holman R, Linong Ji, Kirkman S, Knowler WC, Schatz D, Shaw J, Sobngwi E, Steffes M, Vaccaro O, Wareham N, Zinman B, Kahn R
Diabetes Care 2009;32:1327-1334, Published:Jul-2009, Epub:05-Jun-2009, PMID:19502545, doi:10.2337/dc09-9033
Limitations of Existing Diabetes Treatment
Holman RR
Novo Nordisk Annual Report 2009;30, Published:24-Jun-2009
UKPDS Letter
Addition of Insulin to Oral Therapy in Type 2 Diabetes
Holman RR, Matthews DM, Neil HAW
N Eng J Med 2009;360:418, Published:24-Jun-2009
Predicting 6-year mortality risk in patients with type 2 diabetes: response to Wells et al.
Paul S, Coleman RL, Price HC, Farmer AJ
Diabetes Care 2009;32:e60, Published:May-2009, PMID:19407070, doi:10.2337/dc09-0183
Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw K, Wareham NJ, Griffin SJ
Diabetes Care 2009;32:708-713, Published:Apr-2009, Epub:29-Dec-2008, PMID:19114615, doi:10.2337/dc08-1918
European physicians overestimate life expectancy and the likely impact of interventions in individuals with Type 2 diabetes
Price HC, Thorne KI , Dukat A, Kellett J
Diabetic Medicine 2009;26:453-455, Published:Apr-2009, Epub:27-Feb-2009, PMID:19388980, doi:10.1111/j.1464-5491.2009.02702.x
Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes
Price HC, Coleman RL, Stevens RJ, Holman RR
Diabetologia 2009;52:394-397, Published:Mar-2009, Epub:02-Dec-2008, PMID:19048226, doi:10.1007/s00125-008-1231-5
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Price HC, Holman RR
Nature Clinical Practice Cardiovasc Medicine 2009;6:168-169, Published:Mar-2009, Epub:20-Jan-2009, PMID:19153560, doi:10.1038/ncpcardio1446
HTA Report
Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial
Farmer AJ, Wade AN, French DP, Simon J, Yudkin P, Gray A, Craven A, Goyder L, Holman RR, Mant D, Kinmonth A-L and Neil HAW, on behalf of the DiGEM Trial Group
Health Technology Assessment 2009;13:1-71, Published:Mar-2009, PMID:19254484, doi:10.3310/hta13150
Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes
Hartweg J, Farmer AJ, Holman RR, Neil A
Curr Opin Lipidol 2009;20:30-38, Published:Feb-2009, PMID:19133409, doi:10.1097/MOL.0b013e328321b3be
Community Cardiology Clinics for Secondary Prevention of Coronary Heart Disease and Heart Failure in Primary Care
Khunti K, MD, Stone M, Paul S, Squire I.
Cardiology Review 2009;25:64-67, Published:05-Jan-2009
[Full text]
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA on behalf of the AFORRD study group
Diabetologia 2009;52:50 - 59, Published:Jan-2009, Epub:11-Nov-2008, PMID:19002433, doi:10.1007/s00125-008-1179-5
Prevalence of Glucokinase (GCK) Mutations in Individuals Screened for Fasting Hyperglycaemia
Gloyn AL, van de Bunt M, Stratton IM, Lonie L, Tucker L, Ellard S, Holman RR
Diabetologia 2009;52:172-174, Published:Jan-2009, Epub:11-Nov-2008, PMID:19002431, doi:10.1007/s00125-008-1188-4
Medical Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B
Diabetes Care 2009;32:193-203, Published:Jan-2009, Epub:22-Oct-2008, PMID:18945920, doi:10.2337/dc08-9025
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B
Diabetologia 2009;52:17-30, Published:Jan-2009, Epub:22-Oct-2008, PMID:18941734, doi:10.1007/s00125-008-1157-y
Changing diabetes by improving control: Outcome trials
Holman RR
Journal of Diabetes Nursing 2009;13:39, Published:Jan-2009
2008UKPDS - The first 30 years
Holman RR, Watkins PJ
2008; :ISBN:978-1-4051-9166, Published:07-Apr-2015
The cost-effectiveness a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care
D A Turner, S Paul, M A Stone, A Juarez-Garcia, I Squire, K Khunti
Heart 2008;94:1601-1606, Published:Dec-2008, Epub:01-May-2008, PMID:18450843, doi:10.1136/hrt.2007.125708
4-T Letter
Addition of Insulin to Oral Therapy in Type 2 Diabetes
Holman RR
N Eng J Med 2008;358:1198, Published:05-Nov-2008
[Full text]
Analysis of bedside entertainment services' effect on post cardiac surgery physical activity: a prospective, randomised clinical trial
Sotiris Papaspyros, Shitansu Uppal, Shakeeb A. Khan, Sanjoy Paul, David J. O'Regan
European Journal of Cardiothoracic Surgery 2008;34:1022-1026, Published:Nov-2008, Epub:15-Aug-2008, PMID:18706826, doi:10.1016/j.ejcts.2008.05.042
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel, David R. Matthews and H. Andrew W. Neil
N Eng J Med 2008;359:1577-89, Published:09-Oct-2008, Epub:10-Sep-2008, PMID:18784090, doi:10.1056/nejmoa0806470
Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes
Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel, H. Andrew W. Neil and David R. Matthews
N Eng J Med 2008;359:1565-76, Published:09-Oct-2008, Epub:10-Sep-2008, PMID:18784091, doi:10.1056/nejmoa0806359
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
Robert M. Califf, Mitradev Boolell, Steven M. Haffner, M. Angelyn Bethel, John McMurray, Anil Duggal, Rury R. Holman, for the NAVIGATOR Study Group
Am Heart J 2008;156:623-32, Published:Oct-2008, Epub:09-Sep-2008, PMID:18946890, doi:10.1016/j.ahj.2008.05.017
Determining the most appropriate components for a composite clinical trial outcome
M. Bethel, R. Holman, S. Haffner, R. Califf, A. Huntsman-Labed, T. Hua, J. McMurray
Am Heart J 2008;156:633-40, Published:Oct-2008, Epub:31-Jul-2008, PMID:18926145, doi:10.1016/j.ahj.2008.05.018
Impact of comorbid diabetes on quality of life and perception of angina pain in people with angina registered with general practitioners in the UK
Stone MA, Khunti K, Squire I, Paul S
Qual Life Res 2008;17:887-894, Published:Aug-2008, Epub:17-Jun-2008, PMID:18560992, doi:10.1007/s11136-008-9363-0
The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD. A Pilot 2x2 Factorial understanding risk trial
Hermione C Price, Lynne Tucker, Simon J Griffin and Rury R Holman
Cardiovascular Diabetology 2008;7:21, Published:17-Jul-2008, PMID:18637168, doi:10.1186/1475-2840-7-21
Predictability of price of tea from sensory assessments and biochemical information using data-mining techniques
Sanjoy K Paul
J Sci Food Agric 2008;88:1354-1362, Published:Jun-2008, Epub:09-Apr-2008, doi:10.1002/jsfa.3223
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial
DREAM Trial Investigators; G.R. Dagenais, H.C. Gerstein, R. Holman, A. Budaj, A. Escalante, T. Hedner, M. Keltai, E. Lonn, S. McFarlane, M. McQueen, K. Teo, P. Sheridan, J. Bosch, J. Pogue, S. Yusuf
Diabetes Care 2008;31:1007-1014, Published:May-2008, Epub:11-Feb-2008, PMID:18268075, doi:10.2337/dc07-1868
Rosiglitazone Associated Fractures in Type 2 Diabetes:an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Steven E. Kahn, Bernard Zinman, John M. Lachin, Steven M. Haffner, William H. Herman, Rury R. Holman, Barbara G. Kravitz, Dahong Yu, Mark A. Heise, R. Paul Aftring, Giancarlo Viberti, and for the A Diabetes Outcome Progression Trial (ADOPT) Study Group
Diabetes Care 2008;31:845-851, Published:May-2008, Epub:25-Jan-2008, PMID:18223031, doi:10.2337/dc07-2270
Clinical decisions. Management of type 2 diabetes
Ronald B. Goldberg, Rury Holman, Daniel J. Drucker
N Eng J Med 2008;358:293-7, Published:17-Jan-2008, PMID:18199869, doi:10.1056/NEJMclde0708469
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones
D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin and B. Zinman
Diabetologia 2008;51:8-11, Published:07-Jan-2008, Epub:20-Nov-2007, PMID:18026926, doi:10.1007/s00125-007-0873-z
Erratum in :
Diabetologia 2008;51:522, Print:Mar-2008, doi:10.1007/s00125-007-0917-4
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones
David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin and Bernard Zinman
Diabetes Care 2008;31:173-175, Published:Jan-2008, Epub:22-Oct-2008, PMID:18165348, doi:10.2337/dc08-9016
2007Recommendations for designing tables that report randomized trials
E. S. Johnson, I. M. Stratton
Diabetic Medicine 2007;24:1309-1312, Published:Dec-2007, Epub:01-Nov-2007, PMID:17976200, doi:10.1111/j.1464-5491.2007.02301.x
Cardiovascular Benefits of Metformin
Holman RR
in Metformin - The Gold Standard, Editors CJ Bailey, IW Campbell, JC Chan, JA Davidson, HCS Howlett, P Ritz 2007;15, Published:28-Nov-2007
Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78
Carole A. Cull, Christine C. Jensen, Ravi Retnakaran and Rury R. Holman
Circulation 2007;116:2119-2126, Published:06-Nov-2007, Epub:22-Oct-2007, PMID:17967769, doi:10.1161/CIRCULATIONAHA.107.733428
Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial
Kamlesh Khunti, Margaret Stone, Sanjoy Paul, Jan Baines, Louise Gisborne, Azhar Farooqi, Xiujie Luan and Iain Squire
Heart 2007;93:1398-1405, Published:Nov-2007, Epub:19-Feb-2007, PMID:17309907, doi:10.1136/hrt.2006.106955
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Rury R. Holman, Kerensa I. Thorne, Andrew J. Farmer, Melanie J. Davies, Joanne F. Keenan, Sanjoy Paul, Jonathan C. Levy for the 4-T Study Group
N Eng J Med 2007;357:1716-30, Published:25-Oct-2007, Epub:21-Sep-2007, PMID:17890232, doi:10.1056/NEJMoa075392
[Abstract] [Slides]
GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.
M. Desai, C. A. Cull, V. A. Horton, M. R. Christie, E. Bonifacio, V. Lampasona, P. J. Bingley, J. C. Levy, I. R. Mackay, P. Zimmet, R. R. Holman and A. Clark
Diabetologia 2007;50:2052-2060, Published:Oct-2007, Epub:27-Jul-2007, PMID:17657474, doi:10.1007/s00125-007-0745-6
Stability of soluble adhesion molecules, selectins and C-reactive protein at various temperatures: implications for epidemiological and large-scale clinical studies
Janine Hartweg, Michael Gunter, Rafael Perera, Andrew Farmer, Carole Cull, Casper Schalkwijk, Astrid Kok, Harry Twaalfhoven, Rury Holman and Andrew Neil
Clinical Chemistry 2007;53:1858-60, Published:Oct-2007, Epub:03-Aug-2007, PMID:17675341, doi:10.1373/clinchem.2006.076380
Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes
J. Hartweg, A. J. Farmer, R. Perera1, R. R. Holman and H. A. W. Neil
Diabetologia 2007;50:1593-1602, Published:Aug-2007, Epub:31-May-2007, PMID:17541540, doi:10.1007/s00125-007-0695-z
Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial
Andrew Farmer, Alisha Wade, Elizabeth Goyder, Patricia Yudkin, David French, Anthea Craven, Rury Holman, Ann-Louise Kinmonth, Andrew Neil on behalf of the Diabetes Glycaemic Education and Monitoring Trial Group
BMJ 2007;335:132-6, Published:21-Jul-2007, Epub:25-Jun-2007, PMID:17591623, doi:10.1136/bmj.39247.447431.BE
Outcomes Model / Risk Engine
Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting
The Mount Hood 4 Modeling Group
Diabetes Care 2007;30:1638-1646, Published:Jun-2007, PMID:17526823, doi:10.2337/dc07-9919
Risk Engine
Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes
Ruth L. Coleman, Richard J. Stevens, Ravi Retnakaran, and Rury R. Holman
Diabetes Care 2007;30:1292-1293, Published:May-2007, Epub:08-Feb-2007, PMID:17290036, doi:10.2337/dc06-1358
Role of Lifestyle and Oral Anti Diabetic Agents to Prevent Type 2 Diabetes Mellitus and Cardiovascular Disease
M.Angelyn Bethel, Robert M. Califf
American Journal of Cardiology 2007;99:726-731, Published:01-Mar-2007, Epub:10-Jan-2007, PMID:17317381, doi:10.1016/j.amjcard.2006.09.122
Factors predictive of voiding problems following insertion of tension-free vaginal tape
A. Shukla, S. Paul, A. Nishtar, J. Bibby
Int J Gynaecol Obstet. 2007;96:122-126, Published:Feb-2007, Epub:18-Jan-2007, PMID:17239884, doi:10.1016/j.ijgo.2006.10.013
Meta-analysis of the effects of omega-3 poylunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes
J. Hartweg, A. J. Farmer, R. R. Holman and H. A. W. Neil
Diabetologia 2007;50:250-258, Published:27-Jan-2007, Epub:21-Nov-2006, PMID:17119918, doi:10.1007/s00125-006-0486-y
An association analysis of the HLA gene region in latent autoimmune diabetes in adults
M. Desai, E. Zeggini, V. A. Horton, K. R. Owen, A. T. Hattersley, J. C. Levy, M. Walker, K. M. Gillespie, P. J. Bingley, G. A. Hitman, R. R. Holman, M. I. McCarthy and A. Clark
Diabetologia 2007;50:68-73, Published:Jan-2007, Epub:02-Dec-2006, PMID:17143607, doi:10.1007/s00125-006-0513-z
Metformin as First Choice in oral Diabetes Treatment: the UKPDS experience
Holman R
Journ Annu Diabetol Hotel Dieu 2007;13:13-20, Published:Jan-2007, PMID:18613325
[Full text]
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G for the ADOPT Study Group
N Eng J Med 2006;355:2427-43, Published:07-Dec-2006, Epub:04-Dec-2006, PMID:17145742, doi:10.1056/NEJMoa066224
[Abstract] [Slides]
Erratum in :
N Eng J Med 2007;356:1387-8, Print:29-Mar-2007, doi:10.1056/NEJMx070014
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH for the ADOPT Study Group
Diabetic Medicine 2006;23:1289-1294, Published:Dec-2006, Epub:17-Nov-2006, PMID:17116177, doi:10.1111/j.1464-5491.2006.02022.x
Paraoxonase2 (PON2) Polymorphisms and Development of Renal Dysfunction in Type 2 Diabetes: UKPDS 76
Calle R, McCarthy MI, Banerjee P, Zeggini E, Cull CA, Thorne KI, Wiltshire S, Terra S, Meyer D, Richmond J, Mancuso J, Milos P, Fryburg D, Holman RR
Diabetologia 2006;49:2892-2899, Published:Dec-2006, Epub:03-Oct-2006, PMID:17096118, doi:10.1007/s00125-006-0436-8
Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73
Wright AD, Cull CA, Macleod KM, Holman RR for the UKPDS Group
J Diabetes Complications 2006;20:402-408, Published:Nov-2006, Epub:25-Oct-2006, PMID:17070446, doi:10.1016/j.jdiacomp.2005.08.010
UKPDS Letter
A Clinical Screening Tool Identifies Autoimmune Diabetes in Adults: Response to Fourlanos et al.
Timothy M.E. Davis, Carole A. Cull and Rury R. Holman
Diabetes Care 2006;29:2560, Published:Nov-2006, PMID:17065707, doi:10.2337/dc06-1321
Effect of Ramipril on the Incidence of diabetes
Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR for the DREAM Trial Investigators
N Eng J Med 2006;355:1551-62, Published:12-Oct-2006, Epub:15-Sep-2006, PMID:16980380, doi:10.1056/NEJMoa065061
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR on behalf of the DREAM trial investigators
Lancet 2006;368:1096-105, Published:15-Sep-2006, Epub:20-Sep-2006, PMID:16997664, doi:10.1016/S0140-6736(06)69420-8
Erratum in :
Lancet 2006;368:1770
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR
Diabetologia 2006;49:1761-1769, Published:Aug-2006, Epub:31-May-2006, PMID:16736131, doi:10.1007/s00125-006-0297-1
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes
Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC and the ADOPT Study Group
Diabetes 2006;55:2357-2364, Published:Aug-2006, PMID:16873701, doi:10.2337/db06-0116
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B
Diabetes Care 2006;29:1963-1972, Published:Aug-2006, Epub:27-Jun-2006, PMID:16873813, doi:10.2337/dc06-9912
Erratum in :
Diabetes Care 2006;49:2816-8, Print:Nov-2006
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B
Diabetologia 2006;49:1711-1721, Published:Aug-2006, Epub:27-Jun-2006, PMID:16802130, doi:10.1007/s00125-006-0316-2
Erratum in :
Diabetologia 2006;49:2816-2818, Print:Nov-2006, Epub:13-Sep-2006, doi:10.1007/s00125-006-0415-0
Assessing the Impact of Visual Acuity on Quality of Life in Individuals With Type 2 Diabetes Using the Short Form-36
Clarke PM, Simon J, Cull CA, Holman RR
Diabetes Care 2006;29:1506-1511, Published:Jul-2006, PMID:16801570, doi:10.2337/dc05-2150
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials
Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P
American Heart Journal 2006;152:27-38, Published:Jul-2006, Epub:13-Jul-2006, PMID:16824829, doi:10.1016/j.ahj.2005.09.015
Axillary and tympanic membrane temperature measurements are unreliable early after cardiopulmonary bypass
Khan TA, Vohra HA, Paul S, Rosin MD, Patel RL
European Journal of Anaesthesiology 2006;23:551-554, Published:Jul-2006, Epub:27-Jan-2006, PMID:16438760, doi:10.1017/S0265021505001936
Risk Factors for Renal Dysfunction in Type 2 Diabetes
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR for the UKPDS study group
Diabetes 2006;55:1832-1839, Published:Jun-2006, PMID:16731850, doi:10.2337/db05-1620
The Variable Number of Tandem Repeats Upstream of the Insulin Gene Is a Susceptibility Locus for Latent Autoimmune Diabetes in Adults
Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, Hitman GA, Walker M, Holman RR, McCarthy MI, Clark A
Diabetes 2006;55:1890-1894, Published:Jun-2006, PMID:16731859, doi:10.2337/db06-0089
Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective
Holman RR
Metabolism Clinical and Experimental 2006;55 (Suppl 1):S2-S5, Published:May-2006, Epub:21-Apr-2016, PMID:16631806, doi:10.1016/j.metabol.2006.02.006
Outcomes Model Letter
PROactive Study
Holman RR, Retnakaran R, Farmer A, Stevens RJ
Lancet 2006;367:25-26, Published:07-Jan-2006, Epub:05-Jan-2006, PMID:16399144, doi:10.1016/S0140-6736(06)67914-2
2005A common mitchondrial DNA variant is associated with thinness in mothers and their 20 year old offspring
Parker E, Phillips DI, Cockington RA, Cull C, Poulton J
American Journal of Physiology, Endocrinology & Metabolism 2005;289:E1110-E1114, Published:Dec-2005, Epub:05-Jul-2005, PMID:15998658, doi:10.1152/ajpendo.00600.2004
Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study
Thomason MJ, Biddulph JP, Cull CA, Holman RR
Diabetic Medicine 2005;22:1031-1036, Published:Aug-2005, Epub:02-Mar-2005, PMID:16026369, doi:10.1111/j.1464-5491.2005.01584.x
Risk Engine Short Report
Non-HDL Cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes
Holman RR, Coleman RL, Shine BS, Stevens RJ
Diabetes Care 2005;28:1796-1797, Published:Jul-2005, PMID:15983339, doi:10.2337/diacare.28.7.1796
Outcomes Model / UKPDS 72
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR
Diabetologia 2005;48:868-877, Published:May-2005, Epub:15-Apr-2005, PMID:15834550, doi:10.1007/s00125-005-1717-3
Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes
Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR
Diabetes Care 2005;28:995-1000, Published:May-2005, PMID:15855556, doi:10.2337/diacare.28.5.995
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes
G. F. Bottazzo, E. Bosi, C. A. Cull, E. Bonifacio, M. Locatelli, P. Zimmet, I. R. Mackay, R. R. Holman
Diabetologia 2005;48:703-708, Published:Apr-2005, Epub:12-Mar-2005, PMID:15765222, doi:10.1007/s00125-005-1691-9
Erratum in :
Diabetologia 2005;48:1240, Epub:19-May-2005, doi:10.1007/s00125-005-1808-1
Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control
T. M. E. Davis, A. D. Wright, Z. M. Mehta, C. A. Cull, I. M. Stratton, G. F. Bottazzo, E. Bosi, I. R. Mackay, R. R. Holman
Diabetologia 2005;48:695-702, Published:Apr-2005, Epub:24-Feb-2005, PMID:15729570, doi:10.1007/s00125-005-1690-x
Risk Engine Short Report
Framingham risk equations underestimate coronary heart disease risk in diabetes
R. J. Stevens, R. L. Coleman, R. R. Holman
Diabetic Medicine 2005;22:228, Published:Feb-2005, Epub:19-Jan-2005, PMID:15660747, doi:10.1111/j.1464-5491.2005.01387.x
2004UKPDS 67
Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67)
Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR
Diabetic Medicine 2004;22:306-311, Published:Mar-2005, Epub:02-Dec-2004, PMID:15717879, doi:10.1111/j.1464-5491.2004.01418.x
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
Cull CA, Neil HAW, Holman RR
Diabetic Medicine 2004;21:1368-1371, Published:Dec-2004, Epub:24-Nov-2004, PMID:15569143, doi:10.1111/j.1464-5491.2004.01328.x
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus
Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM for the UK Prospective Diabetes Study Group
Archives of Ophthalmology 2004;122:1631-1640, Published:Nov-2004, PMID:15534123, doi:10.1001/archopht.122.11.1631
Outcomes Model / UKPDS 68
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS 68)
P. M. Clarke, A. M. Gray, A. Briggs, A. J. Farmer, P. Fenn, R. J. Stevens, D. R. Matthews, I. M. Stratton, R. R. Holman
Diabetologia 2004;47:1747-1759, Published:Oct-2004, Epub:27-Oct-2004, PMID:15517152, doi:10.1007/s00125-004-1527-z
Guidelines for computer modeling of diabetes and its complications
Bergemann R, Brown J, Chan W, Clarke P, Eddy D, Herman W, Palmer AJ, Roze S, Stevens R, Zhang P
Diabetes Care 2004;27:2262-2265, Published:Sep-2004, PMID:15333499, doi:10.2337/diacare.27.9.2262
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial
Gerstein HC, Yusuf S, Holman RR, Bosch J, Pogue J; The DREAM Trial Investigators
Diabetologia 2004;47:1519-1527, Published:Sep-2004, Epub:21-Aug-2004, PMID:15322749, doi:10.1007/s00125-004-1485-5
A standardized triglyceride and carbohydrate challenge: response to thanopoulou, karamanos, and roussi
Mohanlal N, Holman RR
Diabetes Care 2004;27:2093, Published:Aug-2004, doi:10.2337/diacare.27.8.2093
Comparative study of prognostic value for coronary disease risk between the U.K. Prospective diabetes study and framingham models: response to Protopsaltis et al.
Stevens RJ, Holman RR
Diabetes Care 2004;27:1844-1845, Published:Jul-2004, PMID:15220283, doi:10.2337/diacare.27.7.1843
A standardized triglyceride and carbohydrate challenge: the oral triglyceride tolerance test
Nina Mohanlal and Rury R. Holman
Diabetes Care 2004;27:89-94, Published:Jan-2004, PMID:14693972, doi:10.2337/diacare.27.1.89
Risk Engine / UKPDS 66
Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR
Diabetes Care 2004;27:201-207, Published:Jan-2004, PMID:14693990, doi:10.2337/diacare.27.1.201
2003Risk Engine
Evaluation of methods for interval estimation of model outputs, with application to survival models
Stevens RJ
Journal of Applied Statistics 2003;30:967-981, Published:Sep-2003, doi:10.1080/0266476032000076100
Poor pregnancy outcome for women with Type 2 diabetes
Hadden DR, Cull CA, Croft DJ, Holman RR
Diabetic Medicine 2003;20:506-507, Published:Jun-2003, Epub:18-Jul-2003, PMID:12786690, doi:10.1046/j.1464-5491.2003.00955_2.x
Outcomes Model / UKPDS 65
The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No 65)
Clarke P, Gray A, Legood R, Briggs A, Holman R
Diabetic Medicine 2003;20:442-450, Published:Jun-2003, Epub:18-Jul-2003, PMID:12786677, doi:10.1046/j.1464-5491.2003.00972.x
Autoantibodies to the islet cell antigen SOX-13 areassociated with duration but not type of diabetes
Davis TM, Mehta Z, Mackay IR, Cull CA, Bruce DG, Fida S, Rowley MJ, Holman RR
Diabetic Medicine 2003;20:198-204, Published:Mar-2003, Epub:10-Mar-2003, PMID:12675663, doi:10.1046/j.1464-5491.2003.00897.x
Intensive control policies for blood pressure and blood glucose concentration in type 2 diabetes are affordable in England
Gray A, Clarke P, Farmer A, Holman RR
Evidence-based Healthcare 2003;7:51-52, Published:Mar-2003, Epub:10-Mar-2003, doi:10.1016/S1462-9410(02)00133-X
Diabetes education and knowledge in patients with type 2 diabetes from the community The Fremantle Diabetes Study
Bruce DG, Davis WA, Cull CA, Davis TM
J Diabetes Complications 2003;17:82-89, Published:Mar-2003, PMID:12614974, doi:10.1016/S1056-8727(02)00191-5
Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR for the UKPDS Group
Kidney International 2003;63:225-232, Published:Jan-2003, PMID:12472787, doi:10.1046/j.1523-1755.2003.00712.x
Fire-and-forget in prevention of coronary heart disease
Karpe F, Holman R.
Lancet 2002;360:1984, Published:14-Dec-2002, Epub:13-Dec-2002, PMID:12493308, doi:10.1016/S0140-6736(02)11890-3
Modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.
Stevens RJ, Stratton IM, Holman RR.
J Diabetes Complications 2002;16:371-376, Published:Nov-2002, Epub:04-Dec-2002, PMID:12477619, doi:10.1016/S1056-8727(02)00161-7
International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling of 2143 patients with ruptured intracranial aneurysms: a randomised trial
Molyneux A, Kerr R; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group, Stratton I, Sandercock P, Clarke M, Shrimpton J, Holman R
J Stroke Cerebrovasc Dis. 2002;11:304-14, Published:Nov-2002, doi:10.1053/jscd.2002.130390
International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling of 2143 patients with ruptured intracranial aneurysms: a randomised trial
Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, Holman R; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group
Lancet 2002;360:1267-1274, Published:26-Oct-2002, PMID:12414200, doi:10.1016/S0140-6736(05)67214-5
The economics of translating trial evidence into practice: costs of implementing more intensive glycaemic and blood pressure control in type 2 diabetes in England
Gray A, Clarke P, Farmer A, Holman R for the United Kingdom Prospective Diabetes Study (UKPDS) Group
British Medical Journal 2002;325:1-6, Published:19-Oct-2002, PMID:12386035, doi:10.1136/bmj.325.7369.860
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes
Viberti G. Kahn SE. Greene DA. Herman WH. Zinman B. Holman RR. Haffner SM. Levy D. Lachin JM. Berry RA. Heise MA. Jones NP. Freed MI.
Diabetes Care 2002;25:1737-1743, Published:Oct-2002, PMID:12351470, doi:10.2337/diacare.25.10.1737
Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated with Improved Outcomes?
Colagiuri S, Cull CA, Holman RR
Diabetes Care 2002;25:1410-1417, Published:Aug-2002, PMID:12145243, doi:10.2337/diacare.25.5.894
Outcomes Model / UKPDS 62
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D
Clarke P, Gray A, Holman R
Medical Decision Making 2002;4:340-349, Published:Aug-2002, PMID:12150599, doi:10.1177/0272989X0202200412
Risk Engine / UKPDS 60
Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine
Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR
Stroke 2002;33:1776-1781, Published:Jul-2002, PMID:12105351, doi:10.1161/01.STR.0000020091.07144.C7
Prevention Conference VI: Diabetes and Cardiovascular Disease
Grundy SM, Garber A, Goldberg R, Havas S, Holman R, Lamendola C, Howard WJ, Savage P, Sowers J, Vega GL
Circulation 2002;105:e153, Published:07-May-2002, PMID:11994266, doi:10.1161/01.CIR.0000014022.85836.96
Hyperglycemia and Other Potentially Modifiable Risk Factors for Peripheral Vascular Disease in Type 2 Diabetes.
Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR
Diabetes Care 2002;25:894-899, Published:May-2002, PMID:11978687, doi:10.2337/diacare.25.5.894
A non-invasive frequent home blood glucose monitor
Lenzen H, Barrow BA, White S, Holman RR.
Practical Diabetes 2002;19:101-103, Published:May-2002, Epub:28-May-2002, doi:10.1002/pdi.312
Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling
Herlihy OM, Barrow BA, Grant PJ, Levy JC
Diabetologia 2002;45:635-641, Published:May-2002, Epub:26-Apr-2002, PMID:12107743, doi:10.1007/s00125-002-0795-8
Human calcium/calmodulin-dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes
Gloyn AL, Desai M, Clark A, Levy JC, Holman RR, Frayling TM, Hattersley AT, Ashcroft SJH
Diabetologia 2002;45:58-583, Published:Apr-2002, PMID:12032636, doi:10.1007/s00125-002-0779-8
Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)
Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR.
Diabetes Care 2002;25:330-336, Published:Feb-2002, PMID:11815505, doi:10.2337/diacare.25.2.330
Erratum in :
Diabetes Care 2002;25:1268, Print:Jul-2002, doi:10.2337/diacare.25.7.1268
Standardization of glycated haemoglobin
Marshall SM, Home PD, Manley SM, Barth JH, John WG.
Annals of Clinical Biochemistry 2002;39:77-79, Published:Jan-2002, PMID:11853199
Analysis of the United Kingdom Prospective Diabetes Study
Holman RR
Endocrine Practice 2002;8 Supplement 1:33-34, Published:Jan-2002, doi:10.4158/EP.8.S1.33
UKPDS Letter
Calculation of coronary risk in Type 2 diabetes: another cause for concern: authors' reply
Holman RR, Manley SE, Stevens RJ on behalf of the UKPDS Study Group
Clinical Science 2002;103:217-219, Published:01-Aug-2001, doi:10.1042/cs1030217v
The UKPDS: implications for the dyslipidaemic patient
Holman R
Acta Diabetologica 2001;38 Suppl 1:S9-S14, Published:Sep-2006, PMID:11829452, doi:10.1007/s005920170003
Risk Engine / UKPDS 56
The UKPDS Risk Engine: a model for the risk of coronary heart disease in type 2 diabetes
Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group
Clinical Science 2001;101:671-679, Published:Dec-2001, PMID:11724655, doi:10.1042/cs1010671
Erratum in :
Clinical Science 2002;102:679, Print:Jun-2002, doi:10.1042/cs1020679
Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.
Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton IM, Jacques P, Breteler MMB, Holman R
Journal of Cardiovascular Risk 2001;8:363-369, Published:Dec-2001, PMID:11873092
[Full text] [Abstract]
Butyrylcholinesterase K variant on chromsome 3q is associated with Type II diabetes in white Caucasian subjects
Hashim Y, Shepherd D, Wiltshire S, Holman RR, Levy JC, Clark A, et al.
Diabetologia 2001;44:2227-2230, Published:Dec-2001, PMID:11793025, doi:10.1007/s001250100033
Erratum in :
Diabetologia 2002;45:459, Print:Mar-2002
Relationship between ethnicity and glycaemic control, lipid profiles and blood pressure during the first nine years of Type 2 diabetes
Davis TM, Cull CA, Holman RR; U.K. Prospective Diabetes Study (UKPDS) Group
Diabetes Care 2001;24:1167-1173, Published:Jul-2001, PMID:11423497, doi:10.2337/diacare.24.7.1167
An economic evaluation of atenolol versus captopril in patients with Type 2 diabetes
Gray A, Clarke P, Raikou M, Stevens R, Neil A, Cull C, Stratton I, Holman R
Diabetes Medicine 2001;18:438-444, Published:Jun-2001, Epub:20-Dec-2001, PMID:11472461, doi:10.1046/j.1464-5491.2001.00485.x
Cost-effective analysis of intensive blood glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 51).
Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, Stratton I, Holman R; UKPDS Group. United Kingdom Prospective Diabetes Study
Diabetologia 2001;44:298-304, Published:Mar-2001, PMID:11317659, doi:10.1007/s001250051617
Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)
Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC.
Diabetic Medicine 2001;18:206-12, Published:Mar-2001, Epub:20-Dec-2001, PMID:11318841, doi:10.1046/j.1464-5491.2001.00449.x
Erratum in :
Diabetic Medicine 2003;20:252, Print:Mar-2003
Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52)
Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR.
Diabetic Medicine 2001;18:178-184, Published:Mar-2001, Epub:20-Dec-2001, PMID:11318837, doi:10.1046/j.1464-5491.2001.00458.x
UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis
Stratton IM, Kohner EM, Aldington SJ, Turner RC, Manley SE, Matthews DR
Diabetologia 2001;44:1546-163, Published:Feb-2001, PMID:11270671, doi:10.1007/s001250051594
2000Possible prevention of type 2 diabetes with acarbose or metformin
Holman RR, North BV, Tunbridge FK
Diabetes 2000;Suppl 1:1078-1079, Published:12-Apr-2005
Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of propectively designed overviews of randomised trials
Blood pressure lowering treatment trialists collaboration
The Lancet 2000;356:1955-1964, Published:09-Dec-2000, PMID:11130523, doi:10.1016/S0140-6736(00)03307-9
Life-expectancy projection by modelling and computer simulation (UKPDS 46)
Stevens R, Adler A, Gray A, Briggs A, Holman R.
Diabetes Research and Clinical Practice 2000;50:S5-S13, Published:Nov-2000, Epub:13-Nov-2000, PMID:11080560, doi:10.1016/S0168-8227(00)00214-X
UKPDS Letter
Seeing what you want to see in randomised controlled trials. Authors' choice of study was ill informed
Holman RR
British Medical Journal 2000;321:1078-1079, Published:28-Oct-2000, PMID:11053192, doi:10.1136/bmj.321.7268.1078
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR
British Medical Journal 2000;321:412-419, Published:12-Aug-2000, PMID:10938049, doi:10.1136/bmj.321.7258.412
[Abstract] [Slides]
Erratum in :
British Medical Journal 2001;322:90, Print:13-Jan-2001
Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR
British Medical Journal 2000;321:405-412, Published:12-Aug-2000, PMID:10938048, doi:10.1136/bmj.321.7258.405
[Abstract] [Slides]
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study
Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR
British Medical Journal 2000;321:412-419, Published:12-Aug-2000, PMID:10938049, doi:10.1136/bmj.321.7258.412
[Abstract] [Slides]
Erratum in :
British Medical Journal 2001;322:90, Print:13-Jan-2001
Effects of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins
Manley SM, Stratton IM, Cull CA, Fighi V, Eeley EA, Matthews DR, Holman RR, Turner RC
Diabetic Medicine 2000;17:518-523, Published:Jul-2000, PMID:10972581, doi:10.1046/j.1464-5491.2000.00320.x
Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycaemia
Peacey SR, Robinson R, Bedford C, Harris ND, MacDonald IA, Holman RR, Heller SR
Diabetes Care 2000;23:1022-1023, Published:Jul-2000, PMID:10895860, doi:10.2337/diacare.23.7.1022
Cost-effective analysis of intensive blood glucose control with metformin in overweight patients with type 2 diabetes.
Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R
British Medical Journal 2000;320:1373-1378, Published:20-May-2000, PMID:10818026, doi:10.1136/bmj.320.7246.1373
Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial
Gray A, Raikou M, McGurire A, Fenn P, Stevens R, Cull C, Stratton IM, Adler AI, Holman RR, Turner RC
British Medical Journal 2000;320:1373-1378, Published:20-May-2000, PMID:10818026, doi:10.1136/bmj.320.7246.1373
1999UKPDS 47
Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47)
Adler AI, Neil AW, Manley SE, Holman RR, Turner RC
Am Heart J 1999;138:S353-S359, Published:11-Sep-2006, PMID:10539797, doi:10.1016/S0002-8703(99)70035-9
Metformin and Risk of Cardiovascular Disease
Turner RC, Holman RR
Cardiology 1999;91:203-204, Published:Sep-1999, Epub:24-Sep-1999, PMID:10516415, doi:10.1159/000006910
Sequence variants of the sarco(endo)plasmic reticulum Ca2+-transport ATPase 3 gene (SERCA3) are associated with Type 2 diabetes in Caucasians
Varadi A, Lebel L, Hashim Y, Mehta Z, Ashcroft SJH, Turner RC
Diabetologia 1999;42:1240-1243, Published:Sep-1999, PMID:10525666, doi:10.1007/s001250051298
Microaneurysms in the development of diabetic retinopathy
Kohner EM, Stratton IM, Adlington SJ, Turner RC
Diabetologia 1999;42:1107-1112, Published:Sep-1999, PMID:10447523, doi:10.1007/s001250051278
UKPDS: What was the question? UK Prospective Diabetes Study
Turner R, Holman R, Butterfield J
Lancet 1999;354:600, Published:14-Aug-1999, PMID:10470732, doi:10.1016/S0140-6736(05)77957-5
Randomised, double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over three years
Holman RR, Cull CA, Turner RC
Diabetes Care 1999;22:960-964, Published:Jul-1999, PMID:10372249, doi:10.2337/diacare.22.6.960
Erratum in :
Diabetes Care 1999;22:1922, Print:Nov-1999
Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control
Diabetes Care 1999;22:1125-1136, Published:Jul-1999, PMID:10388978, doi:10.2337/diacare.22.7.1125
Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)
Turner RC, Cull CA, Frighi V, Holman RR
JAMA 1999;281:2005-2012, Published:02-Jun-1999, PMID:10359389, doi:10.1001/jama.281.21.2005
Risk factors for stroke in non-insulin dependent diabetes mellitus
Davies TME, Millns H, Stratton IM, Holman RR, Turner RC
Arch Intern Med 1999;159:1097-1103, Published:24-May-1999, PMID:10335687, doi:10.1001/archinte.159.10.1097
Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group
Horton VA, Stratton IM, Bottazzo GF, Shattock M, MacKay I, Zimmett P, Manley SE, Holman RR, Turner RC
Diabetologia 1999;42:608-616, Published:May-1999, PMID:10333055, doi:10.1007/s001250051202
Hepatocyte nuclear factor-1alpha (the MODY3 gene) mutations in late onset Type 2 diabetes in the UK.
Cox RD, Sotham L, Hashim Y, Horton V, Mehta Z, Taghavi J, Lathrop M, Turner RC
Diabetes 1999;42:120-121, Published:Jan-1999, PMID:10027593, doi:10.1007/s001250051127
1998UKPDS 38
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
British Medical Journal 1998;317:703-713, Published:12-Sep-1998, PMID:9732337, doi:10.1136/bmj.317.7160.703
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes
British Medical Journal 1998;317:713-720, Published:12-Sep-1998, PMID:9732338, doi:10.1136/bmj.317.7160.713
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes
British Medical Journal 1998;317:720-726, Published:12-Sep-1998, PMID:9732339, doi:10.1136/bmj.317.7160.720
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Lancet 1998;352:837-853, Published:12-Sep-1998, PMID:9742976, doi:10.1016/S0140-6736(98)07019-6
Erratum in :
Lancet 1999;354:602, Print:14-Aug-1999
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
Lancet 1998;352:854-865, Published:12-Sep-1998, PMID:9742977, doi:10.1016/S0140-6736(98)07037-8
Erratum in :
Lancet 1998;352:1558, Print:07-Nov-1998, doi:10.1016/S0140-6736(05)60381-9
Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32)
Diabetes Care 1998;21:1271-1277, Published:Aug-1998, PMID:9702432, doi:10.2337/diacare.21.8.1271
Assessing the potential for alpha-glucosidase inhibitors in prediabetic states
Holman RR
Diabetes Research and Clinical Practice 1998;40:S21-S25, Published:Jul-1998, Epub:07-Aug-1998, PMID:9740498, doi:10.1016/S0168-8227(98)00038-2
Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM
Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC
Diabetes Care 1998;21:810-816, Published:May-1998, PMID:9589246, doi:10.2337/diacare.21.5.810
UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC
Diabetic Medicine 1998;15:297-303, Published:Apr-1998, PMID:9585394, doi:10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W
Risk factors for coronary artery disease in non-insulin dependent diabetes
British Medical Journal 1998 1998;316:823-828, Published:14-Mar-1998, PMID:9549452, doi:10.1136/bmj.316.7134.823
United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors
Archives of Ophthalmology 1998;116:297-303, Published:Mar-1998, PMID:9514482, doi:10.1001/archopht.116.3.297
United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
Annals of internal medicine 1998;128:165-175, Published:01-Feb-1998, PMID:9454524, doi:10.7326/0003-4819-128-3-199802010-00001
UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
Diabetes Care 1998;21:87-92, Published:Jan-1998, PMID:9538975, doi:10.2337/diacare.21.1.87
Progressive Hyperglycaemia: the UKPDS Experience
Holman RR
Consultant (Supp) 1997;37:530-536, Published:11-Sep-2006
Subject Identification and Recruitment for a non-insulin-dependent diabetes prevention trial
Fasting Hyperglycaemia Study group, Hammersley MS, Meyer LC, Morris RJ, Manley SE
Metabolism 1997;46:44-49, Published:Dec-1997, PMID:9439559, doi:10.1016/S0026-0495(97)90317-6
Randomised controlled trial of enforced healthy-living advice in subjects with increased but not diabetic fasting glucose
Fasting hyperglycaemia Study Group, Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC
Metabolism 1997;46:50-55, Published:Dec-1997, PMID:9439560, doi:10.1016/S0026-0495(97)90318-8
Randomised controlled trial of sulphonylurea therapy for subjects with increased fasting glucose levels
FHS group, Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR
Metabolism 1997;46:56-60, Published:Dec-1997, PMID:9439561, doi:10.1016/S0026-0495(97)90319-X
UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
Lancet 1997;350:1288-1293, Published:01-Nov-1997, PMID:9357409, doi:10.1016/S0140-6736(97)03062-6
Erratum in :
Lancet 1998;351:376, Print:31-Jan-1998, doi:10.1016/S0140-6736(05)78287-8
U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex
Diabetes Care 1997;20:1683-1687, Published:Nov-1997, PMID:9353608, doi:10.2337/diacare.20.11.1683
Approach to maintaining comparability of biochemical data during long-term clinical trials
Cull CA, Manley SE, Stratton IM, Neil HAW, Ross IS, Holman RR, Turner RC, Matthews DR
Clinical Chemistry 1997;43:1913-1918, Published:Oct-1997, PMID:9342012
[Full text] [Abstract]
U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM
Diabetes Care 1997;20:1435-1441, Published:Sep-1997, PMID:9283793, doi:10.2337/diacare.20.9.1435
Coronary heart disease and risk factors in NIDDM - experience from the United Kingdom Prospective Diabetes Study
R. C. Turner, H. Millns, R. R. Holman
Diabetologia 1997;40 Supplement 2:S121-S122, Published:Jun-1997, PMID:9248716, doi:10.1007/s001250051424
UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects
J Clin Endocrinol Metab 1997;82:654-657, Published:Feb-1997, PMID:9024271, doi:10.1210/jcem.82.2.3744
UKPDS 21: low prevalence of the mitochondrial transfer RNA gene (tRNA(Leu(UUR))) mutation at position 3243bp in UK Caucasian type 2 diabetic patients
Saker PJ, Hattersley AT, Barrow B, Hammersley MS, Vorton H, Gillmer MD, Turner RC
Diabetic Medicine 1997;14:42-45, Published:Jan-1997, PMID:9017352, doi:10.1002/(SICI)1096-9136(199701)14:1<42::AID-DIA295>3.0.CO;2-T
1996Issues in Management: Diabetes
Holman RR, Neil HAW
Prevention of Cardiovascular Disease. Ed. Lawrence M 1996;OUP:0, Published:11-Sep-2006
UKPDS 19: Heterogeneity in NIDDM: separate contributions of IRS-1 and b3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations
Zhang Y, Wat N, Stratton IM, Warren-Perry MG, Orho M, Groop L, Turner RC
Diabetolgia 1996;39:1505-1511, Published:Dec-1996, PMID:8960833, doi:10.1007/s001250050605
High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population
Saker PJ, Hattersley AT, Barrow B, Hammersley MS, McLellan JA, D Lo YM, Olds RJ, Gillmer MD, Holman RR, Turner RC
Diabetologia 1996;39:1325-1328, Published:Nov-1996, PMID:8932999, doi:10.1007/s001250050577
Hypertension in Diabetes Study (HDS) IV: Therapeutic requirements to maintain tight blood pressure control
Hypertension in Diabetes Study Group
Diabetologia 1996;39:1554-1561, Published:Nov-1996, PMID:8960842, doi:10.1007/s001250050614
The UK Prospective Diabetes Study
Turner RC, Holman RR
Annals of Medicine 1996;28:439-444, Published:Oct-1996, PMID:8949976
Randomized controlled pilot trial of a hand-held, patient-oriented, insulin regimen optimizer
Holman RR, Smale AD, Pemberton E, Riefflin A, Nealon JL
Informatics for Health and Social Care 1996;21:317-326, Published:Oct-1996, PMID:9179835, doi:10.3109/14639239608999292
UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
Diabetic Medicine 1996;13:656-662, Published:Jul-1996, PMID:8840101, doi:10.1002/(SICI)1096-9136(199607)13:7<656::AID-DIA131>3.0.CO;2-5
Frequency of hypoglycemic episodes during intensive therapy with human insulin
Turner RC, Cull CA, Holman RR
Diabetes Care 1996;19:181-182, Published:Feb-1996, PMID:8718446, doi:10.2337/diacare.19.2.181b
UKPDS Letter
U.K. Prospective Diabetes Study
Turner RC, Cull CA, Holman RR
Diabetes Care 1996;19:182-183, Published:Feb-1996, PMID:8718447, doi:10.2337/diacare.19.2.182
United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus
Annals of Internal Medicine 1996;124:136-145, Published:01-Jan-1996, PMID:8554206, doi:10.7326/0003-4819-124-1_Part_2-199601011-00011
Impaired Glucose Tolerance
Holman RR
Diabetic Medicine 1996;13:S5, Published:Jan-1996
Intensive treatment of type 2 diabetes
Turner RC, Rachman J, Holman RR
Home P, Ed. Copenhagen Symposium Diabetes - the Challenge. Copenhage: Medical Forum International 1996;13-16, Published:Jan-1996
1995UKPDS 15
U.K. Prospective Diabetes Study XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM
Dudley CRK, Keavney B, Stratton IM, Turner RC
Kidney International 1995;48:1907-1911, Published:Dec-1995, PMID:8587251, doi:10.1038/ki.1995.490
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease
Diabetes 1995;44:1249-1258, Published:Nov-1995, PMID:7589820, doi:10.2337/diab.44.11.1249
UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM
Keavney BD, Dudley CRK, Stratton IM, Holman RR, Matthews DR, Ratcliffe PJ, Turner RC
Diabetologia 1995;38:948-952, Published:Aug-1995, PMID:7589881, doi:10.1007/BF00400584
Lessons from UK Prospective Diabetes Study
Turner RC, Holman RR
Diabetes Research and Clinical Practice 1995;28:S151-S157, Published:Aug-1995, PMID:8529508, doi:10.1016/0168-8227(95)01105-M
Relative Efficacy of Randomly allocated Diet, Sulphonylurea, Insulin, or Metformin in Patients with newly diagnosed non-insulin dependent diabetes followed for three years
Holman RR, Cull CA, Fox C, Turner RC
British Medical Journal 1995;310:83-88, Published:14-Jan-1995, PMID:7833731, doi:10.1136/bmj.310.6972.83
UK Prospective Diabetes Study: 3-year update
Holman RR for the UKPDS Group
New Horizons in Diabetes Mellitus and Cardiovascular Disease, Current Science Press. Ed Born GVR, Schwartz J. 1995;183-186, Published:Jan-1995
Insulin therapy in Type II diabetes
Holman RR, Turner RC
Diabetes Research and Clinical Practice 1995;28:S179-S184, Published:Jan-1995, PMID:8529512, doi:10.1016/0168-8227(95)01077-Q
1994HDS 3
Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade
Hypertension in Diabetes Study Group
Diabetic Medicine 1994;11:773-782, Published:Oct-1994, PMID:7851072, doi:10.1111/j.1464-5491.1994.tb00352.x
UK Prospective Diabetes Study. XII: Differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes
Meyer LC, Manley SE, Frighi V, Burden F, Neil HAW, Holman RR, Turner RC
Diabetic Medicine 1994;11:670-677, Published:Aug-1994, PMID:7955993, doi:10.1111/j.1464-5491.1994.tb00331.x
UK Prospective Diabetes Study (UKPDS). XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects
Manley SE, Meyer LC, Neil HAW, Ross IS, Turner RC, Holman RR
Diabetic Medicine 1994;11:534-544, Published:Jul-1994, PMID:7955969, doi:10.1111/j.1464-5491.1994.tb02032.x
Optimised Diabetes Therapy Knowledge-Based Systems: Safety Critical Issues
Nealon JL, Jackson-Smale AD, Holman RR
Proc IEE Colloquium on Knowledge-Based Systems for Safety Critical Applications, London 1994;0, Published:Jan-1994
An Advisory Expert System for Diabetes Treatment, Expert Systems 94, Cambridge
Nealon JL, Jackson-Smale AD, Holman RR
Applications and Innovation in Expert Systems II, ed R Milne, SGES Publications 1994;0, Published:Jan-1994
L'Etude UKPDS Sur Le Controle De La Glycemie Et De L'Hypertension Arterielle Dans Le Diabete De type 2: Objectifs, Structure Et Resultats Preminiaires [The UKPDS study on glycemic control and arterial hypertension in type II diabetes: objectives, structure and preliminary results]
Levy JC, Cull CA, Stratton IM, Holman RR, Turner RC
Journ Annu Diabetol Hotel Dieu 1993;123-37, Published:11-Sep-2006, PMID:8331860
Intranasal Insulin in Type 1 Diabetes
Holman RR
International Symposium, Hamburg 1993;138-143, Published:11-Sep-2006
Availability of Type II Diabetic Families for Detection of Diabetes Susceptibility Genes
Cooke JTE, Page RCL, O'Rahilly S, Levy L, Holman RR, Barrow B, Hattersley AT, Shaw JAG, Wainscoat JS, Turner RC
Diabetes 1993;42:1536-1543, Published:Oct-1993, PMID:8375595, doi:10.2337/diab.42.10.1536
UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia
Cull CA, Manley S, Frighi V, Holman RR, Turner RC
Diabetologia 1993;36:1021-1029, Published:Oct-1993, PMID:8243850, doi:10.1007/BF02374494
UK Prospective Diabetes Study (UKPDS). IX: Relationships of urinary albumin and N-acetylglucosaminidase to glycaemia and hypertension at diagnosis of type 2 (non-insulin-dependent) diabetes mellitus and after 3 months diet therapy
UKPDS Study Group
Diabetologia 1993;36:835-842, Published:Sep-1993, PMID:8405755, doi:10.1007/BF00400359
Hypertension in Diabetes Study (HDS) I: Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardio-vascular and diabetic complications
(HDS I) Hypertension in Diabetes Study Group
Journal of Hypertension 1993;11:309-317, Published:Mar-1993, PMID:8387089
[Full text] [Abstract]
Hypertension in Diabetes Study (HDS) II: Increased risk of cardio-vascular complications in hypertensive type 2 diabetic patients
Hypertension in Diabetes Study Group
Journal of Hypertension 1993;11:319-325, Published:Mar-1993, PMID:8387090
[Full text] [Abstract]
Oral Agents and Insulin
Holman RR, Turner RC
Textbook of Diabetes . Ed. Pickup J, Williams G 1991;462-476, Published:11-Sep-2006
UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance
Turner RC, Holman RR, Matthews DR, Oakes SF, Bassett PA, Stratton IM, Cull CA, Manley SE, Frighi V
Diabetologia 1991;34:877-890, Published:Dec-1991, PMID:1778353, doi:10.1007/BF00400195
Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia
Holman RR, Steemson J, Turner RC
Diabetes Res 1991;18:149-53, Published:Dec-1991, PMID:1842749
[Full text] [Abstract]
Autoantibodies to islet amyloid polypeptide in diabetes
Clark A, Yon SM, de Koning EJ, Holman RR
Diabetic Medicine 1991;8:668-673, Published:Aug-1991, PMID:1833120, doi:10.1111/j.1464-5491.1991.tb01675.x
1990Rapid restoration of normoglycaemia using intravenous insulin boluses
Dunnett JM, Steemson J, Sear JW, Turner RC, Holman RR
Diabetes Research 1990;15:151-155, Published:Dec-1990, PMID:2132403
[Full text] [Abstract]
Insulin use in NIDDM. Rationale based on pathophysiology of disease
Turner RC, Holman RR
Diabetes Care 1990;13:1011-1020, Published:Sep-1990, PMID:2226108, doi:10.2337/diacare.13.9.1011
Response of fasting plasma glucose to diet therapy in newly-presenting Type 2 diabetic patients
UKPDS Study Group
Metabolism 1990;39:905-912, Published:Sep-1990, PMID:2392060, doi:10.1016/0026-0495(90)90299-R
New Therapeutic Principles in the Treatment of Type II diabtes
Holman RR
Diab Neutr Metab 1990;3:29-33, Published:Jan-1990
UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors
UKPDS Study Group
Diabetes Research 1990;13:1-11, Published:Jan-1990, PMID:2097090
1988Optimizing blood glucose control in type 2 diabetes: an approach based on fasting blood glucose measurements
Holman RR, Turner RC
Diabetic Medicine 1988;5:582-588, Published:11-Sep-2006, PMID:2974783, doi:10.1111/j.1464-5491.1988.tb01056.x
Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes
Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJS, Holman RR, Turner RC
Diabetes Research 1988;9:151-160, Published:Dec-1988, PMID:3073901
Role of basal insulin supplement in therapy of Type 2 diabetes
Holman RR, Turner RC
Satellite Symposium, Australia 1988;November:138-142, Published:Nov-1988
Finger-prick blood samples: full blood counts in general practice
Blasewicz LW, Sichel J, Rees SG, Isaac P, Holman RR
The Practitioner 1988;232:988-991, Published:22-Sep-1988, PMID:3256848
Diabetes mellitus and anaesthesia. A survey of the peri-operative management of the patient with diabetes mellitus
Dunnett JM, Holman RR, Turner RC, Sear JW
Anaesthesia 1988;43:538-542, Published:Jul-1988, PMID:3046412, doi:10.1111/j.1365-2044.1988.tb06682.x
Characteristics of newly presenting type 2 diabetic patients: estimated insulin sensitivity and islet beta-cell function
UKPDS Study Group
Diabetic Medicine 1988;5:444-448, Published:Jul-1988, PMID:2970917, doi:10.1111/j.1464-5491.1988.tb01025.x
Insulin for the non-insulin dependent?
Holman RR
British Medical Journal 1988;296:1469-1470, Published:21-May-1988, PMID:3132300, doi:10.1136/bmj.296.6634.1469-c
Characteristics of newly-presenting type 2 diabetic patients: male preponderance and obesity at different ages
UKPDS Study Group
Diabetic Medicine 1988;5:154-159, Published:Mar-1988, PMID:2964982, doi:10.1111/j.1464-5491.1988.tb00963.x
Potential benefits of the use of long-acting human insulin in NIDDM
Turner RC, Holman RR
In Proc. 1st International Novo Symposium. Ed R Tattersall 1988;45-49, Published:Jan-1988
Sulphonylurea Failure and Inadequacy
Turner RC, Holman RR, Matthews DR
Excerpta Medica; Satellite Symposium. Ed. D Cameron, S Colagiuri, L Heding, C Kuhl, A Ma, R Mortimer 1988;52-56, Published:Jan-1988
1987Improvement of beta-cell response by sulphonylurea and its rational use in Type II diabetes
Turner RC, Hosker JP, Holman RR
Medicographia 1987;9:42-45, Published:Sep-1987
Sulphonylurea failure in type 2 diabetes: Treatment with a basal insulin supplement
Holman RR, Steemson J, Turner RC
Diabetic Medicine 1987;4:457-462, Published:Sep-1987, PMID:2959438, doi:10.1111/j.1464-5491.1987.tb00909.x
Type II diabetes of early onset: A distinct clinical and genetic syndrome?
O'Rahilly SP, Spivey RS, Holman RR, Nugent Z, Clark A, Turner RC
British Medical Journal 1987;294:923-928, Published:11-Apr-1987, PMID:3107658, doi:10.1136/bmj.294.6577.923
Pen-sized digital 30-second blood glucose meter.
Matthews DR, Bown E, Watson A, Holman RR, Steemson J, Hughes S, Scott D
Lancet 1987;1:778-779, Published:04-Apr-1987, PMID:2882186, doi:10.1016/S0140-6736(87)92802-9
Identifying the cause
O'Rahilly SP, Holman RR
Mims Magazine 1987;15 March:23-26, Published:Mar-1987
Glycosylated Haemoglobin Measurement on Blood Samples taken by patients: An Additional Aid to Assessing Diabetic Control
Holman RR, Jelfs R, Causier PM, Moore JC, Turner RC
Diabetic Medicine 1987;4:71-73, Published:Jan-1987, PMID:2951227, doi:10.1111/j.1464-5491.1987.tb00834.x
Quantitative modelling of endocrine diseases as exemplified by diabetes
Turner RC, Rudenski AS, Holman RR, Matthews DR, O'Rahilly SP
Clinical Endocrinology Oxf 1987;Jan 26:107-116, Published:Jan-1987, PMID:3542309, doi:10.1111/j.1365-2265.1987.tb03644.x
No glycaemic benefit from guar administration in non-insulin-dependent diabetics
Holman RR, Steemson J, Darling P, Turner RC
Diabetes Care 1987;10:68-71, Published:Jan-1987, PMID:3032537, doi:10.2337/diacare.10.1.68
Traitement du diabete non insulino-dependant [Treatment of non-insulin-dependent diabetes]
Turner RC, Holman RR
Journ Annu Diabetol Hotel Dieu 1987;129-301, Published:Jan-1987, PMID:3613374
1986Quantifying early diabetic retinopathy
Howard-Williams JR, Orde-Peckar C, Holman RR, Turner RC, Bron AJ
Diabetologia 1986;29:761-766, Published:Nov-1986, PMID:3817334, doi:10.1007/BF00873213
Diabetes nomenclature: Classification or grading of severity?
Turner RC, Holman RR, Matthews DR, O'Rahilly SP, Rudenski AS, Braund WJ
Diabetic Medicine 1986;3:216-220, Published:May-1986, PMID:2951172, doi:10.1111/j.1464-5491.1986.tb00747.x
Glycosylated haemoglobin: comparison of five different methods, including measurement on capillary blood samples.
Moore JC, Brown EG, Outlaw MC, Jelfs R, Holman RR, Turner RC
Annals Clinical Biochemistry 1986;23:85-91, Published:Jan-1986, PMID:3767256, doi:10.1177/000456328602300110
Optimizing conventional insulin regimens to improve control
Turner RC, Holman RR
Brittle Diabetes, Ed. John Pickup, Backwell Scientific 1985;200-213, Published:11-Sep-2006
The Christmas Feast
Rees SG, Holman RR, Turner RC
British Medical Journal 1985;291:1764-1765, Published:21-Dec-1985, PMID:3936575, doi:10.1136/bmj.291.6511.1764
United Kingdom Prospective Diabetes Study. III. Prevalence of hypertension and hypotensive therapy in patients with newly diagnosed diabetes. A multicenter study
UKPDS Study Group
Hypertension 1985;7:11-13, Published:Nov-1985, PMID:4077242, doi:10.1161/01.HYP.7.6_Pt_2.II8
U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study
UKPDS Study Group
Diabetes 1985;34:793-798, Published:Aug-1985, PMID:2862087, doi:10.2337/diab.34.8.793
Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man
Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Daring P, Brown EG, Turner RC
Diabetologia 1985;28:401-411, Published:Jul-1985, PMID:3899824, doi:10.1007/BF00280882
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC
Diabetologia 1985;28:412-419, Published:Jul-1985, PMID:3899825, doi:10.1007/BF00280883
Patient-orientated metered capillary blood collection
Holman RR, Steemson J, Darling P, Turner RC
Annals Clinical Biochemistry 1985;22:141-143, Published:Mar-1985, PMID:4004103, doi:10.1177/000456328502200205
Physiology of insulin secretion: problems of quantity and timing
Matthews DR, Connolly AAP, Holman RR, Turner RC
Netherlands Journal of medicine 1985;28:20-24, Published:Feb-1985, PMID:3892333
A practical guide to basal and prandial insulin therapy
Holman RR, Turner RC
Diabetic Medicine 1985;2:45-53, Published:Jan-1985, PMID:2951066, doi:10.1111/j.1464-5491.1985.tb00592.x
Diabetic coma
Holman RR, Blazewicz LW
Medical Forum 1985;16:4-6, Published:Jan-1985
The Oxford experience with Ultratard
Holman RR
Proceedings Third International Hvidore Symposium 1985;0, Published:Jan-1985
1984Non-uniform distribution of islet amyloid in the pancreas of 'maturity-onset' diabetic patients
Clark A, Holman RR, Matthews DR, Hockaday TDR, Turner RC
Diabetologia 1984;27:527-528, Published:Nov-1984, PMID:6391995, doi:10.1007/BF00290389
Insulin treatment of maturity onset diabetes
Turner RC, Holman RR
Minerva Endocrinol 1984;9:233-240, Published:Apr-1984, PMID:6390137
Human ultralente insulin
Holman RR, Steemson J, Darling P, Reeves WG, Turner RC
British Medical Journal 1984;288:665-668, Published:03-Mar-1984, PMID:6421424, doi:10.1136/bmj.288.6418.665
1983UKPDS 01
UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year
UKPDS Study Group
Diabetologia 1983;24:404-411, Published:Jun-1983, PMID:6350078, doi:10.1007/BF00257337
Prevention of deterioration of renal and sensory nerve function by more intensive management of insulin-dependent diabetics: a two year randomised prospective study
Holman RR, Dornan TL, Mayon-White V, Howard-Williams J, Orde-Peckar C, Jenkins L, Steemson J, Rolfe R, Smith B, Barbour D, Mcpherson K, Poon PYW, Rizza C, Mann JI, Knight AH, Bron AJ, Turner RC
Lancet 1983;1:204-208, Published:29-Jan-1983, PMID:6130244, doi:10.1016/S0140-6736(83)92586-2
1982A regular meal and insulin infusion regimen: its use in the treatment of acute-onset ketotic diabetes and in stabilization of poorly controlled established diabetic subjects
Davis TME, Holman RR, Eaton PM, Turner RC
Diabetes Care 1982;5:492-496, Published:Sep-1982, PMID:6821354
Induced basal normoglycaemia and altered platelet aggregation in maturity-onset diabetes
Evans RJ, Lane J, Holman RR, Turner RC
Diabetes Care 1982;5:433-437, Published:Jul-1982, PMID:6818012, doi:10.2337/diacare.5.4.433
Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes
Turner RC, Matthews DR, Holman RR, Peto J
Lancet 1982;1:596-598, Published:13-Mar-1982, PMID:6121186, doi:10.1016/S0140-6736(82)91753-6
Ultralente-based insulin regimes in insulin-dependent diabetics
Turner RC, Phillips M, Jones R, Dornan TL, Holman RR
Insulin Update. Skyler JS, Ed. Princeton NJ Excerpta medica 1982;157-174, Published:Jan-1982
Treatment of non-insulin dependent diabetes by insulin
Turner RC, Holman RR
Insulin Update. Skyler JS. Ed. Princeton NJ Excerpta Medica 1982;233-246, Published:Jan-1982
Vibration sensory threshold: a guide to the adequacy of dialysis
Read DJ, Feest TG, Holman RR
XIX edition of the proceedings of the EDTA 1982;19:253-7, Published:Jan-1982, PMID:6348739
[Full text] [Abstract]
1981Insulin infusion pump
Holman RR, Turner RC
Lancet 1981;2:41, Published:04-Jul-1981, PMID:6113411, doi:10.1016/S0140-6736(81)90272-5
The basal plasma glucose: A simple relevant index of diabetes
Holman RR, Turner RC
Clinical Endocrinology 1981;14:279-286, Published:Mar-1981, PMID:7021010, doi:10.1111/j.1365-2265.1981.tb00196.x
Holman RR
Emergency Medicine. Ed Evans RG, Butterworths 1981;29-34, Published:Jan-1981
1980Fasting Blood Glucose Concentrations and treatment of maturity-onset diabetes
Howe-Davies S, Muir A, Holman RR, Turner RC
British Medical Journal 1980;280:1148, Published:03-May-1980, PMID:7427124, doi:10.1136/bmj.280.6223.1148-a
Survival in sinoatrial disorder (sick sinus syndrome)
Shaw DB, Holman RR, Gowers JI
British Medical Journal 1980;1:139-141, Published:19-Jan-1980, PMID:7357290, doi:10.1136/bmj.280.6208.139
1979HOMA Calculator
Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations
Turner RC, Holman RR, Matthews DR, Peto J, Hockaday TDR
Metabolism 1979;28:1086-1096, Published:Nov-1979, PMID:386029, doi:10.1016/0026-0495(79)90146-X
A simple and rational twice daily insulin regime. Distinction between basal and meal insulin requirements
Phillips M, Simpson RW, Holman RR, Turner RC
Quarterly Journal of Medicine 1979;191:493-506, Published:Jul-1979, PMID:396545
[Full text] [Abstract]
Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes
Holman RR, Turner RC
Diabetes 1979;28:227-230, Published:Mar-1979, PMID:446907, doi:10.2337/diab.28.3.227
1978Home blood sampling for plasma glucose assay in control of diabetes
Howe-Davies S, Holman RR, Phillips M, Turner RC
British Medical Journal 1978;2:596-598, Published:26-Aug-1978, PMID:568013, doi:10.1136/bmj.2.6137.596
Basal normoglycaemia attained with chlorpropamide in mild diabetes
Holman RR, Turner RC
Metabolism 1978;27:539-547, Published:May-1978, PMID:565457, doi:10.1016/0026-0495(78)90020-3
Beta cell function during insulin or chlorpropamide treatment in maturity onset diabetes
Turner RC, Holman RR
Diabetes 1978;27:241-246, Published:Feb-1978, PMID:344115, doi:10.2337/diab.27.1.S241
Serum lipids in treated diabetic children and their families
Mann JI, Holman RR, Honour AJ, Hughson WG, Thorogood M, Smith A, Baum JD
Clinical Endocrinology 1978;8:27-33, Published:Jan-1978, PMID:627089, doi:10.1111/j.1365-2265.1978.tb01347.x
Automatic lancet for capillary blood sampling
Turner RC, Holman RR
Lancet 1978;2:712, Published:30-Sep-1878, PMID:80637, doi:10.1016/S0140-6736(78)92706-X
1977Diabetes: The quest for basal normoglycaemia
Holman RR, Turner RC
Lancet 1977;1:469-474, Published:26-Feb-1977, PMID:65573, doi:10.1016/S0140-6736(77)91954-7
The fundamental importance of the basal plasma glucose in diabetes
Holman RR, Turner RC
Oxford Medical School Gazette 1977;29:18-23, Published:Jan-1977
Comparison of treatment of mild diabetes with a basal insulin supplement or sulphonylurea
Holman, R.R., Harris, E., Harding, P., Turner, R.C.
Clinical Science and Molecular Medicine 1977;52: , Published:Jan-1977
Treatment of type IV hypertriglyceridaemia with insulin
Turner, R.C., Holman, R.R., Harding, P.A.
Clinical Science and Molecular Medicine 1977;53: , Published:Jan-1977
1976Pathophysiology of diabetes
Turner, R.C., Holman, R.R.
Lancet 1976;2:856, Published:24-May-2011, PMID:61532, doi:10.1016/S0140-6736(76)91247-2
Insulin rather than glucose homeostasis in the pathophysiology of diabetes
Turner RC, Holman RR
Lancet 1976;1:1272-1274, Published:12-Jun-1976, PMID:73696, doi:10.1016/S0140-6736(76)91739-6
Beta-cell improved by supplementing basal insulin secretion in mild diabetes
Turner RC, McCarthy ST, Holman RR, Harris E
British Medical Journal 1976;1:1252-1254, Published:22-May-1976, PMID:1268654, doi:10.1136/bmj.1.6020.1252
1975Early life of the 'battered child'
Holman RR, Kanwar S
Archives of Disease in childhood 1975;50:78-80, Published:Jan-1975, PMID:1124946, doi:10.1136/adc.50.1.78